Catamaran Corp (CCT.TO) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Catamaran Corp (CCT.TO)

0.00

-0.00 (0.00%)

9 watching

DON'T BUY

Not a big fan of medical technology information systems as so many have had good stories, but never made any money.

BUY ON WEAKNESS

Likes the company. Have had some pretty good traction. Likes the space. Would buy under $2.

BUY

Ranks very well in the database. Year-over-year earnings growth is up 40%. ROE is expected to be 41%.

TOP PICK

Earnings growth is consistent 65% of earnings is recurring which is very high. Very cheap on a multiples basis.

BUY

A bit of an overhang in that there is a lot of stock for sale. Starting to get traction with their customers. Might go to $3.50/4 long-term. An acquisition target.

BUY

Has done very well and thinks there is still opportunity. In the top 8% of the database. Earnings are expected to grow from 13¢ to 17¢. Continuing to work on some very large contracts and hopefully they will be closed in the new year.

TOP PICK

Has delivered 2 very profitable quarters, 3¢ a share and are looking for them to earn 12¢ 13¢ for the Feb year-end and .20¢ next year. Probably will be a takeover.

WAIT

There is some profit taking going on. There is a big overhang in that some dealers are try to get rid of a block which is putting short-term pressure on the stock. Still a good story. This space is pretty strong. Expected to be acquired ultimately.

BUY

Ranks high in the model. Earnings are forecast to grow from 0.14¢ 0.17¢. A 15% earnings growth against a 15 P/E, gives a good P. E. growth. Year-over-year sales growth is pretty good.

BUY

Likes the business. They understand the dynamics of the industry. A lot of opportunity for them to continue to grow top and bottom. Good price. A little bit risky.

DON'T BUY

A pretty tough industry to consistently make money in. Has delivered, but feels the shares are a little pricey.

BUY

Ranks as #6 in the Canadian database on techs. Still thinks there is good opportunity going forward. Earnings are expected to grow from $0.08 to $.13 per share. They are bidding on some very interesting contracts.

DON'T BUY

Would prefer at a lower price.

BUY

New management has turned the company around. Starting to get an accelerating contract win situation. (Do back office transaction between pharmacies, payer, insurance company, etc. Good product.) Winning market share.

BUY

60% of their revenue is recurring. Strong transaction based. Still pretty good opportunities. Should be more upside.

Showing 121 to 135 of 143 entries

Wealthica The ultimate 360° Tracker Your financial life in one place, automatically

Most Recent Experts

Jim Cramer - Mad Money

CNBC

John Zechner

J. Zechner & Assoc

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Keith Richards

ValueTrend Wealth Management

Joe Terranova

Virtus Investment Partners

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Summer Sale

Catamaran Corp (CCT.TO)